1. Immunogenicity and safety of an inactivated virus vaccine against SARS-CoV-2 in patients with autoimmune rheumatic diseases
- Author
-
Tatiana do Nascimento Pedrosa, Ester Cerdeira Sabino, Emily Figueiredo Neves Yuki, Rosa Maria Rodrigues Pereira, Eloisa Bonfa, Nadia E. Aikawa, Carolina Torres Ribeiro, Percival D. Sampaio-Barros, Carla G. S. Saad, Ana Cristina Medeiros-Ribeiro, Solange R. G. Fusco, Alberto José da Silva Duarte, Giordano B. H. Deveza, Sandra Gofinet Pasoto, Clovis A. Silva, Leila Antonangelo, Marta Heloísa Lopes, Esper G. Kallas, Priscila T Rojo, Danieli Andrade, Victor Adriano de Oliveira Martins, and Samuel Katsuyuki Shinjo more...
- Subjects
Virus vaccine ,business.industry ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Immunogenicity ,Medicine ,In patient ,business ,Virology - Abstract
CoronaVac(SARS-CoV-2 inactivated vaccine) has been largely used as the main immunogen for COVID-19 in several countries. However, its immunogenicity in immunocompromised individuals has not been established. This was a prospective controlled study of 910 adult ARD patients and 182 age- and sex-matched control group(CG) who received two doses of CoronaVac in a 28-days interrval. Anti-SARS-Cov-2 IgG and neutralizing antibodies were assessed at each vaccine shot and 6 weeks after the 2nd dose. Vaccine adverse events(AE) were similar in both groups. We observed significant lower anti-SARS-Cov-2 IgG seroconversion(70.4% vs. 95.5%,p more...
- Published
- 2021
- Full Text
- View/download PDF